Gary Herman

8.2k total citations
58 papers, 2.6k citations indexed

About

Gary Herman is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Oncology. According to data from OpenAlex, Gary Herman has authored 58 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Surgery and 15 papers in Oncology. Recurrent topics in Gary Herman's work include Diabetes Treatment and Management (25 papers), Peptidase Inhibition and Analysis (15 papers) and Pancreatic function and diabetes (10 papers). Gary Herman is often cited by papers focused on Diabetes Treatment and Management (25 papers), Peptidase Inhibition and Analysis (15 papers) and Pancreatic function and diabetes (10 papers). Gary Herman collaborates with scholars based in United States, United Kingdom and Belgium. Gary Herman's co-authors include John A. Wagner, Arthur Bergman, Bingming Yi, Keith Gottesdiener, Karen Snyder, Kenneth C. Lasseter, Michael Tanen, Wesley Tanaka, Peter P. Stein and Michael J. Davies and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Nature Communications.

In The Last Decade

Gary Herman

55 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Herman United States	27	1.8k	905	758	718	423	58	2.6k
Michael Mark Germany	26	2.1k 1.2×	1.2k 1.4×	1.2k 1.6×	352 0.5×	226 0.5×	52	3.1k
Riccardo Perfetti United States	32	3.0k 1.7×	1.5k 1.7×	2.7k 3.5×	421 0.6×	358 0.8×	96	4.3k
Mark Kipnes United States	31	2.9k 1.6×	1.2k 1.4×	1.3k 1.8×	717 1.0×	577 1.4×	57	4.3k
Baptist Gallwitz Germany	20	1.9k 1.1×	812 0.9×	708 0.9×	671 0.9×	251 0.6×	87	2.4k
Wesley Tanaka United States	19	867 0.5×	946 1.0×	411 0.5×	357 0.5×	505 1.2×	33	2.8k
Klaus A. Dugi Germany	39	2.9k 1.7×	1.4k 1.6×	1.6k 2.1×	806 1.1×	370 0.9×	72	4.4k
Leo Thomas Germany	19	1.1k 0.6×	697 0.8×	557 0.7×	379 0.5×	144 0.3×	46	2.0k
Shweta Urva United States	19	1.9k 1.1×	1.1k 1.3×	785 1.0×	141 0.2×	799 1.9×	45	2.8k
Eseng Lai United States	20	620 0.4×	474 0.5×	410 0.5×	136 0.2×	260 0.6×	60	1.8k
Xinhua Zhang China	31	475 0.3×	1.2k 1.3×	315 0.4×	334 0.5×	159 0.4×	138	2.9k

Countries citing papers authored by Gary Herman

Since Specialization

Citations

This map shows the geographic impact of Gary Herman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Herman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Herman more than expected).

Fields of papers citing papers by Gary Herman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Herman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Herman. The network helps show where Gary Herman may publish in the future.

Co-authorship network of co-authors of Gary Herman

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Herman. A scholar is included among the top collaborators of Gary Herman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Herman. Gary Herman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trotter, Dinko González, Stephen Donahue, Chris Wynne, et al.. (2025). GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. Nature Communications. 16(1). 4376–4376. 2 indexed citations

Wipperman, Matthew F., Kaitlyn Gayvert, Amanda Atanasio, et al.. (2024). Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy. Allergy. 79(4). 894–907. 12 indexed citations

O’Brien, Meagan P., Andrea T. Hooper, Eduardo Forleo‐Neto, et al.. (2023). Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection. Open Forum Infectious Diseases. 10(12). ofad598–ofad598. 1 indexed citations

Somersan-Karakaya, Selin, Eleftherios Mylonakis, Ernesto Oviedo‐Orta, et al.. (2023). Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial. Open Forum Infectious Diseases. 10(5). ofad211–ofad211. 1 indexed citations

Brown, Elizabeth R., Meagan P. O’Brien, Flonza Isa, et al.. (2023). A Prospective Study of Key Correlates for Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases. 10(7). ofad271–ofad271.

Cho, Yong‐Yeon, Paul Maruff, John T. Connell, et al.. (2011). Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology. 218(3). 513–524. 31 indexed citations

Kauh, Eunkyung, Lori Mixson, Sudha S. Shankar, et al.. (2011). Short‐term metabolic effects of prednisone administration in healthy subjects. Diabetes Obesity and Metabolism. 13(11). 1001–1007. 17 indexed citations

Herman, Gary, Goutam C. Mistry, Bingming Yi, et al.. (2010). Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology. 71(3). 429–436. 29 indexed citations

Nunes, Irene, James A. Bolognese, Deborah L. Miller, et al.. (2010). Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure. Journal of the American Society of Hypertension. 4(6). 311–318. 6 indexed citations

10.

Mistry, Goutam C., Arthur Bergman, Wei Zheng, et al.. (2008). Sitagliptin, an dipeptidyl peptidase‐4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects. British Journal of Clinical Pharmacology. 66(1). 36–42. 42 indexed citations

11.

Hanefeld, M, et al.. (2007). Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Current Medical Research and Opinion. 23(6). 1329–1339. 139 indexed citations

12.

Krishna, Rajesh, Arthur Bergman, Patrick Larson, et al.. (2007). Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects. The Journal of Clinical Pharmacology. 47(2). 165–174. 56 indexed citations

13.

Bergman, Arthur, Goutam C. Mistry, Wen‐Lin Luo, et al.. (2007). Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers. Biopharmaceutics & Drug Disposition. 28(6). 307–313. 14 indexed citations

14.

Herman, Gary, Peter P. Stein, Nancy A. Thornberry, & John A. Wagner. (2007). Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin. Clinical Pharmacology & Therapeutics. 81(5). 761–767. 135 indexed citations

15.

Greenberg, Howard, et al.. (2007). Human Pharmacokinetics and Interconversion of Enantiomers of MK‐0767, a Dual PPARα/γ Agonist. The Journal of Clinical Pharmacology. 47(3). 323–333. 7 indexed citations

16.

Herman, Gary, et al.. (2006). Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Current Medical Research and Opinion. 22(10). 1939–1947. 77 indexed citations

17.

Herman, Gary, Arthur Bergman, Fang Liu, et al.. (2006). Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects. The Journal of Clinical Pharmacology. 46(8). 876–886. 146 indexed citations

18.

Herman, Gary, C. Melinda Stevens, Koen Vandyck, et al.. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology & Therapeutics. 78(6). 675–688. 414 indexed citations

19.

Bonzelius, Frank, et al.. (2001). Identification of Discrete Classes of Endosome-derived Small Vesicles as a Major Cellular Pool for Recycling Membrane Proteins. Molecular Biology of the Cell. 12(4). 981–995. 54 indexed citations

20.

Kaneda, Yudai, Frank Bonzelius, Claire Desnos, et al.. (1995). Recycling of Synaptic Vesicle Membrane Components. Cold Spring Harbor Symposia on Quantitative Biology. 60(0). 379–387. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact